Scientific Program (All times are CET)
| Session 1: Smoldering myeloma: what’s next? | |
| How to define high risk smoldering myeloma Irene Ghobrial, USA |
|
| How to treat high risk smoldering myeloma Maria Victoria Mateos, Spain |
|
| Round table discussion Irene Ghobrial, USA, Maria Victoria Mateos, Spain, S. Vincent Rajkumar, USA, Mario Boccadoro, Italy |
|
| Session 2: Therapy of transplant eligible patients | |
| Novel induction regimens Philippe Moreau, France |
|
| Maintenance therapy Graham Jackson, UK |
|
| Round table discussion Philippe Moreau, France, Graham Jackson, UK, Paul Richardson, USA, Francesca Gay, Italy |
|
| Session 3: Plenary lecture | |
| Role and perspectives of MRD in myeloma Jesus San Miguel, Spain |
|
| Round table discussion Jesus San Miguel, Spain, Herve Avet-Loiseau, France, Bruno Paiva, Spain, Kwee Yong, UK |
|
| Industry-sponsored symposium (GSK) To complete the post-symposium survey – click here |
|
| Session 4: Therapy of transplant ineligible patients | |
| Frailty assessment Sonja Zweegman, The Netherland |
|
| Novel regimens in elderly patients Thierry Facon, France |
|
| Round table discussion Sonja Zweegman, The Netherland, Thierry Facon, France, Alessandra Larocca, Italy, Maria Victoria Mateos, Spain |
|
| Session 5: Selected oral communications | |
| UPDATED PHASE 1B RESULTS FROM CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-4528 CAR-T CELL THERAPY IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) Presenter: Andrzej Jakubowiak, USADREAMM-2: BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITHMULTIPLE MYELOMA REFRACTORY TO PROTEASOME INHIBITORS, IMMUNOMODULATORY AGENTS, AND REFRACTORY/INTOLERANT TO ANTI-CD38 MAB, INCLUDING SUBGROUPS WITH RENAL IMPAIRMENT (RI) AND HIGH-RISK (HR) CYTOGENETICS Presenter: Lonial Sagar, USADREAMM-5: PLATFORM TRIAL EVALUATING BELANTAMAB MAFODOTIN (A BCMA-DIRECTED IMMUNO-CONJUGATE) IN COMBINATION WITH NOVEL AGENTS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) Presenter: Ira Gupta, USAFINAL ANALYSIS OF A PHASE I-b STUDY OF ISATUXIMAB COMBINED WITH CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): (NCT-02332850) Presenter: Tom Martin, USA OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) IN ROUTINE CLINICAL PRACTICE REMAIN COMPARABLE TO THE OUTCOMES REPORTED IN THE PHASE 3 TOURMALINE-MM1 STUDY HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO POMALIDOMIDE AND/OR AN ANTI-CD38 MONOCLONAL ANTIBODY (MAB) – FINAL PRIMARY ANALYSIS ORAL IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (IRD) VERSUS PLACEBO-RD FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS INELIGIBLE FOR TRANSPLANT: THE MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TOURMALINE MM2 TRIAL |
|
| Industry-sponsored symposium (Sanofi) | |
| Session 6: Therapy of relapsed/refractory myeloma | |
| Anti-CD38-based combinations Saad Usmani, USA |
|
| IMiDs: past, present and future Xavier Leleu, France |
|
| Round table discussion Saad Usmani, USA, Xavier Leleu, France, Enrique M. Ocio, Spain, Cyril Touzeau, France, Shaji Kumar, USA |
|
| Session 7: Immunotherapy for myeloma | |
| Bispecific antibodies Luciano Costa, USA |
|
| CAR-T Cells Noopur Raje, USA |
|
| Round table discussion Luciano Costa, USA, Noopur Raje, USA, Salomon Manier, France, Sagar Lonial, USA |
|
| Session 8: Plenary lecture | |
| Multiple Myeloma Excellence Award ceremony Presented to: Saad Usmani, USA by Congress Co-Chairs |
|
| Multiple Myeloma Excellence Award lecture Saad Usmani, USA |
|
| Management of Al amyloidosis: what’s new? Giampaolo Merlini, Italy |
|
| Industry-sponsored symposium (Adaptive Biotechnologies) |